Alcon And STAAR Announce Expiration Of HSR Waiting Period For Acquisition

Author: Benzinga Newsdesk | September 30, 2025 07:43am

Alcon (NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ:STAA) ("STAAR"), the manufacturer of the Implantable Collamer® Lens (ICL), today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR), in connection with Alcon's acquisition of STAAR, expired at 11:59 p.m. ET on September 29, 2025.

As previously announced, under the terms of the agreement, Alcon will purchase all outstanding shares of STAAR common stock for $28 per share in cash, which represents approximately a 59% premium to STAAR's 90-day volume weighted average price and a 51% premium to the closing price of STAAR common stock on August 4, 2025 (the day prior to the transaction announcement). The transaction represents a total equity value of approximately $1.5 billion.

Posted In: ALC STAA